| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.056 | 0.06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.085 | 0.07 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |